|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:country
|
gptkb:Japan
|
|
gptkbp:focus
|
gptkb:diabetes
immunology
infectious diseases
neurology
cardiovascular diseases
|
|
gptkbp:founded
|
1678
|
|
gptkbp:headquartersLocation
|
gptkb:Osaka,_Japan
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
JP3469000008
|
|
gptkbp:keyPerson
|
gptkb:Masayuki_Mitsuka
|
|
gptkbp:logo
|
Mitsubishi Tanabe Pharma logo.svg
|
|
gptkbp:memberOf
|
gptkb:Mitsubishi_Group
|
|
gptkbp:mergedInto
|
2007
|
|
gptkbp:netIncome
|
¥41.2 billion (FY2022)
|
|
gptkbp:notableProduct
|
gptkb:Remicade
gptkb:Envarsus_XR
Radicava (edaravone)
|
|
gptkbp:numberOfEmployees
|
7,372
|
|
gptkbp:parentCompany
|
gptkb:Mitsubishi_Chemical_Holdings
|
|
gptkbp:predecessor
|
gptkb:Mitsubishi_Pharma
gptkb:Tanabe_Seiyaku
|
|
gptkbp:products
|
pharmaceutical drugs
|
|
gptkbp:revenue
|
¥423.8 billion (FY2022)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:subsidiary
|
gptkb:Mitsubishi_Tanabe_Pharma_America,_Inc.
gptkb:Mitsubishi_Tanabe_Pharma_Europe_Ltd.
|
|
gptkbp:tradedOn
|
TYO:4508
|
|
gptkbp:website
|
https://www.mt-pharma.co.jp/
|
|
gptkbp:bfsParent
|
gptkb:edaravone
|
|
gptkbp:bfsLayer
|
5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mitsubishi Tanabe Pharma
|